Immunogenicity, safety, and tolerability of two trivalent subunit inactivated influenza vaccines: A phase III, observer-blind, randomized, controlled multicenter study

Viral Immunology

Volumn 25, Issue 3, 2012, Pages 216-225

  Tregnaghi, Miguel W ^a   Stamboulian, Daniel ^b   Vanadía, Paula Carina ^a   TregnaghO i, Jorge Pablo ^a   Calvari, Miriam ^a   Fragapane, Elena ^c   Casula, Daniela ^c   Pellegrini, Michele ^c   Groth, Nicola ^c  

^a Centro de Desarrollo de Proyectos Avanzados Cordoba   (Argentina)

^b Centro de Estudios Infectologicos   (Argentina)

^c NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

ADOLESCENT; ADULT; ANTIBODY DETECTION; ANTIBODY TITER; ARGENTINA; ARTHRALGIA; ARTICLE; BRONCHITIS; CHILD; CHILL; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECCHYMOSIS; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; GASTROENTERITIS; HEADACHE; HEMAGGLUTINATION INHIBITION TEST; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE SWELLING; MALAISE; MALE; MULTICENTER STUDY; NONHUMAN; NORMAL HUMAN; PHARYNGITIS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; RHINOPHARYNGITIS; SEROCONVERSION; SIDE EFFECT; SINGLE BLIND PROCEDURE; SWEATING; VACCINATION; VIRUS STRAIN; VOMITING;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; ARGENTINA; CHILD; CHILD, PRESCHOOL; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; TREATMENT OUTCOME; VACCINATION; VACCINES, INACTIVATED; VACCINES, SUBUNIT; YOUNG ADULT;

EID: 84862266979     PISSN: 08828245     EISSN: 15578976     Source Type: Journal    
DOI: 10.1089/vim.2011.0063     Document Type: Article

References (35)

1. Beyer WE, Nauta JJ, Palache AM, Giezeman KM, and Osterhaus AD: Immunogenicity and safety of inactivated influenza vaccines in primed populations: A systematic literature review and meta-analysis. Vaccine 2011;29:5785-5792.
2. Black S, Della Cioppa G, Malfroot A, et al.: Safety of MF59-adjuvanted versus non-adjuvanted influenza vaccines in children and adolescents: an integrated analysis. Vaccine 2010;28):7331-7336.
3. Bridges CB, Winquist AG, Fukuda K, Cox NJ, Singleton JA, and Strikas RA: Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000;49(RR-3):1-38; quiz CE31-CE37.
4. Chaloupka I, Schuler A, Marschall M, and Meier-Ewert H: Comparative analysis of six European influenza vaccines. Eur J Clin Microbiol Infect Dis 1996;15:121-127. (Pubitemid 26098745)
5. Dille JH: A worksite influenza immunization program. Impact on lost work days, health care utilization, and health care spending. AAOHN J 1999;47:301-309.
6. Dong PM, Li YQ, Zheng TZ, et al.: [Comparative study on safety and immunogenicity between influenza subunit vaccine and split vaccine]. Zhonghua Liu Xing Bing Xue Za Zhi 2003;24:570-573.
7. Durando P, Fenoglio D, Boschini A, et al.: Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults. Clin Vaccine Immunol 2008;15:253-259. (Pubitemid 352025530)
8. Ferguson NM, Cummings DA, Fraser C, Cajka JC, Cooley PC, and Burke DS: Strategies for mitigating an influenza pandemic. Nature 2006;442:448-452. (Pubitemid 44264793)
9. Fiore AE, Shay DK, Broder K, et al.: Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2008. MMWR Recomm Rep 2008;57(RR-7):1-60.
10. Fiore AE, Uyeki TM, Broder K, et al.: Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep 2010;59:1-62.
11. Fleming DM, and Elliot AJ: The impact of influenza on the health and health care utilisation of elderly people. Vaccine 2005;23(Suppl 1):S1-S9.
12. Fluvirin (influenza virus vaccine). Full Prescribing Information. Novartis Vaccines and Diagnostics, Liverpool, U.K., 2010.
13. Frey S, Vesikari T, Szymczakiewicz-Multanowska A, Lattanzi M, Izu A, Groth N, and Holmes S: Clinical efficacy of cell culture-derived and egg-derived inactivated subunit influenza vaccines in healthy adults. Clin Infect Dis 2010;51:997-1004.
14. Harper SA, Fukuda K, Uyeki TM, Cox NJ, and Bridges CB: Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2004;53(RR-6):1-40.
15. Harper SA, Fukuda K, Uyeki TM, Cox NJ, and Bridges CB: Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005;54(RR-8):1-40.
16. Heikkinen T, Silvennoinen H, Peltola V, et al.: Burden of influenza in children in the community. J Infect Dis 2004; 190:1369-1373. (Pubitemid 39332175)
17. Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, Weintraub E, and Bridges CB: The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 2007;25:5086-5096. (Pubitemid 46879994)
18. Monto AS, and Maassab HF: Ether treatment of type B influenza virus antigen for the hemagglutination inhibition test. J Clin Microbiol 1981;13:54-57. (Pubitemid 11176658)
19. Muennig PA, and Khan K: Cost-effectiveness of vaccination versus treatment of influenza in healthy adolescents and adults. Clin Infect Dis 2001;33:1879-1885. (Pubitemid 33105128)
20. Nichol KL, Margolis KL, Lind A, et al.: Side effects associated with influenza vaccination in healthy working adults. A randomized, placebo-controlled trial. Arch Intern Med 1996;156:1546-1550.
21. Novartis Vaccines. Data on file, 2011.
22. Palmer DF, Dowle WR, Coleman MT, and Schild GC: Advances in laboratory technicals for immunological diagnostics. Atlanta: U.S. Dept. of Health, Education, and Welfare; 1975, 25-62.
23. Pellegrini M, Nicolay U, Lindert K, Groth N, and Della Cioppa G: MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. Vaccine 2009;27:6959-6965.
24. Poehling KA, Edwards KM, Weinberg GA, et al.: The under-recognized burden of influenza in young children. N Engl J Med 2006;355:31-40.
25. Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2011;60:1128-1132.
26. Reichert TA, Sugaya N, Fedson DS, Glezen WP, Simonsen L, and Tashiro M: The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med 2001;344:889-896. (Pubitemid 32224397)
27. Schmier J, Li S, King JC Jr, Nichol K, and Mahadevia PJ: Benefits and costs of immunizing children against influenza at school: an economic analysis based on a large-cluster controlled clinical trial.HealthAff (Millwood) 2008;27:w96-w104. (Pubitemid 351490370)
28. SmithNM, Bresee JS, Shay DK, Uyeki TM, Cox NJ, and Strikas RA: Prevention and Control of Influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2006;55(RR-10):1-42.
29. Spila-Alegiani S, Salmaso S, Rota MC, Tozzi AE, and Raschetti R: Reactogenicity in the elderly of nine commercial influenza vaccines: results from the Italian SVEVA study. Study for the evaluation of adverse events of influenza vaccination. Vaccine 1999;17:1898-1904. (Pubitemid 29172358)
30. Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, and Fukuda K: Influenza-associated hospitalizations in the United States. JAMA 2004;292:1333-1340. (Pubitemid 39223224)
31. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, and Fukuda K: Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003;289:179-186. (Pubitemid 36068705)
32. Treanor J, and Wright PF: Immune correlates of protection against influenza in the human challenge model. Dev Biol (Basel) 2003;115:97-104.
33. U.S. Food and Drug Administration. Guidance for Industry "Clinical Data Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines" May 2007. U.S. Department of Health and Human Services. Available at: http://www.vaccinesmarket.com/wp-content/uploads/vaccine-guidance/ ucm091990.pdf. Accessed August 5, 2011.
34. World Health Organization: Influenza vaccines. WHO position paper. Wkly Epidemiol Rec 2005;33:279-287.
35. Zhu FC, Zhou W, Pan H, et al.: Safety and immunogenicity of two subunit influenza vaccines in healthy children, adults and the elderly: a randomized controlled trial in China. Vaccine 2008;26:4579-4584.